**Supplementary Table S1. Diagnostic potential of S1 and S2 specific CD4 and CD8 T cell subsets in discrimination Convalescent patients and unexposed donors.**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **T cell Subset** | **Sensitivity** | **Specificity** | **AUC** | **Cut-off** | **P value** |
| CD4+ PDL1+CD25+ (S1-nil | 60 (42.3 - 75.4) | 85.7 (CI 48.6 - 99.27) | 0.7071 | 0.3 | 0.0916 |
| CD4+ PDL1+CD25+ (S2-nil) | 53.3 (CI 36.1 - 69.7) | 85.7 (CI 48.6 - 99.27) | 0.7405 | 0.11 | **0.05** |
| CD4+ CD134+CD25+(S1-nil) | 46.6 (CI 30.2 - 63.8) | 100 (CI 64.5 - 100) | 0.7214 | 0.76 | 0.0714 |
| CD4+ CD134+CD25+(S2-nil) | 56.6 (CI 39.2 - 72.6) | 85.7 (CI 48.6 - 99.27) | 0.6881 | 0.06 | 0.125 |
| CD4+ PDL1+CD11a+(S1-nil) | 66.6 (CI 48.7 - 80.7) | 71.4 (CI 35.8 - 94.9) | 0.6333 | 0.255 | 0.2776 |
| CD4+ PDL1+CD11a+(S2-nil) | 80 (CI 62.6 - 90.4) | 57.1 (CI 25.0 - 84.1) | 0.6667 | 0.015 | 0.1747 |
| CD8+ PDL1+CD25+ (S1-nil | 16.6 (CI 7.3 -33.5) | 100 (CI 64.5 - 100) | 0.6 | 0.07 | 0.415 |
| CD8+ PDL1+CD25+ (S2-nil) | 16.6 (CI 7.3 -33.5) | 100 (CI 64.5 - 100) | 0.5238 | 0.14 | 0.842 |
| CD8+ CD134+CD25+(S1-nil) | 70 (CI 52.1 - 83.3) | 4208 (CI 15.8 - 74.9) | 0.5476 | 0.01 | 0.6982 |
| CD8+ CD134+CD25+(S2-nil) | 46.6 (CI 30.2 - 63.8) | 71.4 (CI 35.8 - 94.9) | 0.6 | 0.015 | 0.415 |
| CD8+ PDL1+CD11a+(S1-nil) | 53.3 (CI 36.1 -69.7) | 71.4 (CI 35.8 - 94.9) | 0.6024 | 0.86 | 0.404 |
| CD8+ PDL1+CD11a+(S2-nil) | 80 (CI 62.9 - 90.4) | 57.14 (CI 25.0 - 84.1) | 0.6238 | 0.015 | 0.313 |

**Supplemental Figure S1:**

A picture containing text, screenshot, map, diagram

Description automatically generated

A picture containing text, screenshot, line

Description automatically generated

**A picture containing colorfulness, screenshot, rectangle, square

Description automatically generated**

**Supplemental Figure S1:** Heatmaps represent the responses ofCD4+ and CD8+ subsets, IFN-γ ELISpot and percentage of lysis by the cytotoxicity assay from 12 HLA-A2 positive convalescent patients. Heatmaps show background-subtracted responses. Continuous color shading for each patient represents the magnitude of response. Note that patient 15 is a convalescent patient that did not show measurable response by IFN-γ ELISpot and AIM FC assays to S1 and S2 but positive IFN-γ ELISpot response to the HLA-A2 peptides.